pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·9h ago·1 min read
save

Fifth Circuit Court Rules in Favor of Providers on No Surprises Act Arbitration, May Increase Payments

Aug 12, 2026·read at STAT ↗RegulatoryPositive

The U.S. Court of Appeals for the Fifth Circuit issued a decision that sides with health-care providers in a lawsuit over the No Surprises Act.

The case stemmed from a 2022 Texas Medical Association suit challenging the federal rule that calculates the qualifying payment amount (QPA) used in arbitration.

The court found the government’s instructions were erroneous and held that QPAs should not include "ghost rates," placeholder amounts that providers do not actually bill.

By removing these low placeholder rates, the ruling could raise the amounts insurers are required to pay in arbitration, potentially increasing revenue for hospitals and physicians.

Federal agencies will now have to revisit the arbitration methodology, and the decision may influence future enforcement of the No Surprises Act.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Providers notch No Surprises Act legal win that could boost their pay”

read at STAT ↗
541 words · retrieved 8h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Protara Therapeutics, Inc.7
topics
MelanomaVaccineVaccines

related stories

  • 1d agoMedicaid will stop paying for some gender-affirming care for transgender minorsSTAT
  • 1d agoAura, Schrödinger trim workforcesBioSpace
  • 2d agoTrump returns to controversial vaccine policy with order questioning childhood scheduleSTAT
  • 6d agoOpinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he wasSTAT
  • Aug 3STAT+: BioNTech names Guido Oelkers its new CEOSTAT